On January 21, 2009, the California Supreme Court decided that it would not review a remarkable California appeals court decision that a brand-name drug manufacturer could be liable for an adverse event the plaintiff suffered as a result of taking a generic version of the drug, if the physician foreseeably relied upon the brand-name drug company’s labeling. We previously reported on the First Appellate District in the Court of Appeal in the State of California decision.
